Risk assessment of over-the-counter cannabinoid-based cosmetics: Legal and regulatory issues governing the safety of cannabinoid-based cosmetics in the UAE

AC-42
Names
	Preferred IUPAC name 4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)-piperidine
Identifiers
CAS Number	244291-63-2 [ChemSpider];
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL1242950;
ChemSpider	8123931;
IUPHAR/BPS	289;
PubChem CID	9948320;
CompTox Dashboard (EPA)	DTXSID901336790 ;
	InChI InChI=1S/C20H31NO/c1-3-4-9-18-12-15-21(16-13-18)14-7-11-20(22)19-10-6-5-8-17(19)2/h5-6,8,10,18H,3-4,7,9,11-16H2,1-2H3 Key: ANTKBACNWQHQJE-UHFFFAOYSA-N;
	SMILES O=C(C=1C=CC=CC1C)CCCN2CCC(CC2)CCCC;
Properties
Chemical formula	C20H31NO
Molar mass	301.474 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

AC-42 is a selective, allosteric agonist of the M1 muscarinic acetylcholine receptor. AC-42 was the first selective M1 agonist to be discovered and its derivatives have been used to study the binding domain of the M1 receptor.^[1]^[2]^[3]

References

^ Decker, Michael; Holzgrabe, Ulrike (2012). "M1 muscarinic cetylcholine receptor allosteric modulators as potential therapeutic opportunities for treating Alzheimer's disease". MedChemComm. 3 (7): 752. doi:10.1039/c2md20025b.
^ Sams, Anette G.; Hentzer, Morten; Mikkelsen, Gitte K.; Larsen, Krestian; Bundgaard, Christoffer; Plath, Niels; Christoffersen, Claus T.; Bang-Andersen, Benny (9 September 2010). "Discovery of N -{1-[3-(3-Oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): An Allosteric Muscarinic M 1 Receptor Agonist with Unprecedented Selectivity and Procognitive Potential". Journal of Medicinal Chemistry. 53 (17): 6386–6397. doi:10.1021/jm100697g. PMID 20684563.
^ Daval, Sandrine B.; Valant, Céline; Bonnet, Dominique; Kellenberger, Esther; Hibert, Marcel; Galzi, Jean-Luc; Ilien, Brigitte (8 March 2012). "Fluorescent Derivatives of AC-42 To Probe Bitopic Orthosteric/Allosteric Binding Mechanisms on Muscarinic M1 Receptors" (PDF). Journal of Medicinal Chemistry. 55 (5): 2125–2143. doi:10.1021/jm201348t. PMID 22329602.

[1] Decker, Michael; Holzgrabe, Ulrike (2012). "M1 muscarinic cetylcholine receptor allosteric modulators as potential therapeutic opportunities for treating Alzheimer's disease". MedChemComm. 3 (7): 752. doi:10.1039/c2md20025b.

[2] Sams, Anette G.; Hentzer, Morten; Mikkelsen, Gitte K.; Larsen, Krestian; Bundgaard, Christoffer; Plath, Niels; Christoffersen, Claus T.; Bang-Andersen, Benny (9 September 2010). "Discovery of N -{1-[3-(3-Oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): An Allosteric Muscarinic M 1 Receptor Agonist with Unprecedented Selectivity and Procognitive Potential". Journal of Medicinal Chemistry. 53 (17): 6386–6397. doi:10.1021/jm100697g. PMID 20684563.

[3] Daval, Sandrine B.; Valant, Céline; Bonnet, Dominique; Kellenberger, Esther; Hibert, Marcel; Galzi, Jean-Luc; Ilien, Brigitte (8 March 2012). "Fluorescent Derivatives of AC-42 To Probe Bitopic Orthosteric/Allosteric Binding Mechanisms on Muscarinic M1 Receptors" (PDF). Journal of Medicinal Chemistry. 55 (5): 2125–2143. doi:10.1021/jm201348t. PMID 22329602.

[1]

[2]

[3]